DOI: https://doi.org/10.22141/2309-8147.2.1.2014.173674

Using of anti VEGF-medications in treatment of choroid neovascularization

N.G. Zavgorodnya, I.A. Poplavska, L.E. Sargevska, M.B. Bezuglyi, D. V. Martynov

Abstract


Nowadays, new methods of treatment of choroid neovascularization are being actively developed and introduced in exudative form of age-related macular degeneration (AMD) complicated myopia, diabetic retinopathy and postthrombotic retinopathy. Medications that block vascular endothelial growth factor (VEGF), which is the main link in the pathogenesis of retinal neovascularization and hyper filtration, have become widespread.
Considering this, anti-VEGF medications have found their application in the treatment of choroid neovascularization in clinical practice. Today, two preparations that block VEGF: selective (pegaptanib) and non-selective (ranibizumab) are used mostly common.
The purpose of this investigation was to study the effectiveness of anti-VEGF medications in patients with choroid neovascularization of different genesis.
The treatment results of 56 patients (56 eyes) with choroid neovascularization associated with various diseases of the retina have been presented in this project. Pegaptanib ("Makugen") was used for the treatment of 35 patients (35 eyes), ranibizumab ("Lucentis") - for the rest (21 eyes). According to fluorescein angiography the subretinal neovascular membrane was in all eyes in the stage of activity. The effectiveness of the treatment was assessed by visometry, ophthalmoscopy, optical coherence tomography and fluorescein angiography. Application of intravitreal injection of pegaptanib improves visual acuity in 65% of cases in patients with choroid neovascularization and exudation, application of ranibizumab - in 7 % of cases. According to optic coherence tomography reduction of the retina thickness after injection into the vitreous body of pegaptanib is achieved in 53%, after ranibizumab - in 62% of cases. The suppression of activity of subretinal neovascular membrane by results of fluorescein angiography - in 26% and 38% respectively. So, in most cases the using of pegaptanib and ranibizumab promotes the improvement or stabilization of visual functions and regression of neovascularization and exudation in patients with choroid neovascularization and exudation of different genesis
The application of both selective and non-selective anti-VEGF medications renders substantial positive effect in patients with choroid neovascularization is safe and promising direction in treatment of this group of patients.


Keywords


choroid neovascularization, exudative age-related macular degeneration, complicated myopia, diabetic retinopathy, post-thrombotic retinopathy, blocker of vascular endothelial growth factor (VEGF)

References


Аверьянов Д.А. Оптическая когерентная томография / Д.А. Аверьянов, Алпатов С.А., Букина В.В. [и др.]. - Иркутск, 2005. - 112 с.

Алпатов С. А. Возрастная макулярная дегенерация / С.А. Алпатов, А.Г. Щуко, Е.М. Урнева // Москва: ГЭОТАР-Медиа, 2010. - 112 с.

Бирнгрубер Р. Принципы лечения ВМД: от ФДТ до интравитреальных anti-VEGF-инъекций / Материалы 111-го всероссийского семинара «Макула2008». - С. 189—197.

Бойко Э. В. Роль и место анти-VEGF терапии в современном подходе к лечению интраокулярной неоваскуляризации различного генеза / Э. В. Бойко, С. В.Сосновский, О. В. Филохина [и др.] // Материалы научной конференции, посвященной 190-летнему юбилею основания кафедры офтальмологии Военно-медицинской академии им. С. М. Кирова «Поражения органа зрения».- Санкт-Петербург, 2008.-С. 31—32.

Нероев В.В.Современные представления и подходы к лечению возрастной макулярной дегенерации / В.В. Нероев, М.В. Рябина, К.Р. Чиковани [и др.] //Российский офтальмологический журнал. - 2008 . - Т. 1, № 1. - С. 6-9.

Пасечникова Н.В. Лазерное лечение при патологии глазного дна. - К.- 2007. - 206 с.

Balatskaya N. Photodynamic therapy for treatment subretinal neovascularization / Balatskaya N., Avetisov S., Budzinskaya M. [et al.] // Proceedings of SPIE. - 2007. - Vol. 6632. - Therapeutic Laser Applications and Laser-Tissue Interactions III663212.

Rosenfeld P. J. Ranibizumab for neovascular agerelated macular Degeneration / P. J. Rosenfeld, D. M. Brown, J. S. Heier [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - P. 1419–1431.

Wong T. The natural history and prognosis of neovascular agerelated macular degeneration: a systematic review of the literature and meta-analysis / T. Wong, U. Chakravarthy, R. Klein [et al.] // Ophthalmology. - 2008. - Vol. 115. - P. 116–126.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта